黄芩苷-妥布霉素联合用药对耐碳青霉烯类抗菌机制的研究
Anti-bacterial mechanism of baicalin-tobramycin combination on carbapenem-resistant .
作者信息
Jin Li-Min, Shen Hui, Che Xing-Ying, Jin Ye, Yuan Chun-Mei, Zhang Neng-Hua
机构信息
Laboratory Department, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, Zhejiang Province, China.
出版信息
World J Clin Cases. 2023 Jun 16;11(17):4026-4034. doi: 10.12998/wjcc.v11.i17.4026.
BACKGROUND
() is an important cause of nosocomial infections, and contributes to high morbidity and mortality, especially in intensive care units. is considered a 'critical' category bacterial pathogen by the World Health Organization to encourage an urgent need for research and development of new antibiotics against its infections.
AIM
To investigate the effectiveness of baicalin combined with tobramycin therapy as a potential treatment method for carbapenem-resistant (CRPA) infections.
METHODS
Polymerase chain reaction (PCR) and RT-PCR were used to detect the expression levels of drug-resistant genes (including , and ) and biofilm-related genes (including , and ) in CRPA that confer resistance to tobramycin, baicalin and tobramycin combined with baicalin (0, 1/8, 1/4, 1/2 and 1MIC).
RESULTS
There was a correlation between biofilm formation and the expression of biofilm-related genes. In addition, , , , , and that confer biofilm production under different concentrations in CRPA were significantly correlated. The synergistic effect of baicalin combined with tobramycin was a significant down-regulation of , , , and .
CONCLUSION
Baicalin combined with tobramycin therapy can be an effective treatment method for patients with CRPA infection.
背景
（）是医院感染的重要原因，会导致高发病率和高死亡率，尤其是在重症监护病房。世界卫生组织将其视为“关键”类别的细菌病原体，以促使迫切需要研发针对其感染的新型抗生素。
目的
探讨黄芩苷联合妥布霉素治疗作为耐碳青霉烯类（CRPA）感染潜在治疗方法的有效性。
方法
采用聚合酶链反应（PCR）和逆转录聚合酶链反应（RT-PCR）检测耐妥布霉素、黄芩苷以及妥布霉素与黄芩苷联合使用（0、1/8、1/4、1/2和1MIC）的CRPA中耐药基因（包括、和）和生物膜相关基因（包括、和）的表达水平。
结果
生物膜形成与生物膜相关基因的表达之间存在相关性。此外，CRPA中在不同浓度下产生生物膜的、、、、和显著相关。黄芩苷联合妥布霉素的协同作用是对、、、和的显著下调。
结论
黄芩苷联合妥布霉素治疗可为CRPA感染患者提供一种有效的治疗方法。
Zotero 插件